Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours
Abstract Background Infection is a devastating complication of endoprosthetic replacement (EPR) in orthopaedic oncology. Surgical treatments include debridement and/or one- or two-stage exchange. This study aims to determine the infection-free survival after surgical treatment for first and recurren...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Journal of Orthopaedic Surgery and Research |
| Online Access: | https://doi.org/10.1186/s13018-022-03446-1 |
| _version_ | 1811171657704800256 |
|---|---|
| author | Tariq Azamgarhi Simon Warren Will Aston Rob Pollock Craig Gerrand |
| author_facet | Tariq Azamgarhi Simon Warren Will Aston Rob Pollock Craig Gerrand |
| author_sort | Tariq Azamgarhi |
| collection | DOAJ |
| description | Abstract Background Infection is a devastating complication of endoprosthetic replacement (EPR) in orthopaedic oncology. Surgical treatments include debridement and/or one- or two-stage exchange. This study aims to determine the infection-free survival after surgical treatment for first and recurrent EPR infections and identify the risk factors associated with infection recurrence. Methods This single-centre cohort study included all patients with primary bone sarcomas or metastatic bone disease treated for infected EPR between 2010 and 2020. Variables included soft tissue status using McPherson classification, tumour type, silver coating, chemotherapy, previous surgery and microorganisms identified. Data for all previous infections were collected. Survival analysis, with time to recurrent infection following surgical treatment, was calculated at 1, 2 and 4 years. Cox regression analysis was used to assess the influence of different variables on recurrent infection. Results The cohort included 99 patients with a median age of 44 years (29–58 IQR) at the time of surgical treatment. The most common diagnoses were osteosarcoma and chondrosarcoma. One hundred and thirty-three surgical treatments for first or subsequent infections were performed. At 2 years of follow-up, overall success rates were as follows: two-stage exchange 55.3%, one-stage exchange 45.5%, DAIR with an exchange of modular components 44.6% and DAIR without exchange of modular components 24.7%. Fifty-one (52%) patients were infection-free at the most recent follow-up. Of the remaining 48 patients, 27 (27%) were on antibiotic suppression and 21 (21%) had undergone amputation. Significant risk factors for recurrent infection were the type of surgical treatment, with debridement alone as the highest risk (HR 4.75: 95%CI 2.43–9.30; P < 0.001); significantly compromised soft tissue status (HR 4.41: 95%CI 2.18–8.92; P = 0.001); and infections due to Enterococcus spp.. (HR 7.31: 95%CI 2.73–19.52); P = 0.01). Conclusions Two-stage exchange with complete removal of all components where feasible is associated with the lowest risk of recurrent infection. Poor soft tissues and enterococcal infections are associated with higher risks of recurrent infection. Treatment demands an appropriate multidisciplinary approach. Patients should be counselled appropriately about the risk of recurrent infection before embarking on complex treatment. |
| first_indexed | 2024-04-10T17:17:36Z |
| format | Article |
| id | doaj.art-c033ac7e167345e38ad08e9ef90aa42a |
| institution | Directory Open Access Journal |
| issn | 1749-799X |
| language | English |
| last_indexed | 2024-04-10T17:17:36Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Orthopaedic Surgery and Research |
| spelling | doaj.art-c033ac7e167345e38ad08e9ef90aa42a2023-02-05T12:19:01ZengBMCJournal of Orthopaedic Surgery and Research1749-799X2023-01-0118111210.1186/s13018-022-03446-1Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumoursTariq Azamgarhi0Simon Warren1Will Aston2Rob Pollock3Craig Gerrand4Pharmacy Department, Royal National Orthopaedic Hospital NHS TrustBone Infection Unit, Royal National Orthopaedic Hospital NHS TrustDivision of Orthopaedic Oncology, Royal National Orthopaedic Hospital NHS TrustDivision of Orthopaedic Oncology, Royal National Orthopaedic Hospital NHS TrustDivision of Orthopaedic Oncology, Royal National Orthopaedic Hospital NHS TrustAbstract Background Infection is a devastating complication of endoprosthetic replacement (EPR) in orthopaedic oncology. Surgical treatments include debridement and/or one- or two-stage exchange. This study aims to determine the infection-free survival after surgical treatment for first and recurrent EPR infections and identify the risk factors associated with infection recurrence. Methods This single-centre cohort study included all patients with primary bone sarcomas or metastatic bone disease treated for infected EPR between 2010 and 2020. Variables included soft tissue status using McPherson classification, tumour type, silver coating, chemotherapy, previous surgery and microorganisms identified. Data for all previous infections were collected. Survival analysis, with time to recurrent infection following surgical treatment, was calculated at 1, 2 and 4 years. Cox regression analysis was used to assess the influence of different variables on recurrent infection. Results The cohort included 99 patients with a median age of 44 years (29–58 IQR) at the time of surgical treatment. The most common diagnoses were osteosarcoma and chondrosarcoma. One hundred and thirty-three surgical treatments for first or subsequent infections were performed. At 2 years of follow-up, overall success rates were as follows: two-stage exchange 55.3%, one-stage exchange 45.5%, DAIR with an exchange of modular components 44.6% and DAIR without exchange of modular components 24.7%. Fifty-one (52%) patients were infection-free at the most recent follow-up. Of the remaining 48 patients, 27 (27%) were on antibiotic suppression and 21 (21%) had undergone amputation. Significant risk factors for recurrent infection were the type of surgical treatment, with debridement alone as the highest risk (HR 4.75: 95%CI 2.43–9.30; P < 0.001); significantly compromised soft tissue status (HR 4.41: 95%CI 2.18–8.92; P = 0.001); and infections due to Enterococcus spp.. (HR 7.31: 95%CI 2.73–19.52); P = 0.01). Conclusions Two-stage exchange with complete removal of all components where feasible is associated with the lowest risk of recurrent infection. Poor soft tissues and enterococcal infections are associated with higher risks of recurrent infection. Treatment demands an appropriate multidisciplinary approach. Patients should be counselled appropriately about the risk of recurrent infection before embarking on complex treatment.https://doi.org/10.1186/s13018-022-03446-1 |
| spellingShingle | Tariq Azamgarhi Simon Warren Will Aston Rob Pollock Craig Gerrand Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours Journal of Orthopaedic Surgery and Research |
| title | Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours |
| title_full | Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours |
| title_fullStr | Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours |
| title_full_unstemmed | Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours |
| title_short | Risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours |
| title_sort | risk factors for recurrent infection in the surgical treatment of infected massive endoprostheses implanted for musculoskeletal tumours |
| url | https://doi.org/10.1186/s13018-022-03446-1 |
| work_keys_str_mv | AT tariqazamgarhi riskfactorsforrecurrentinfectioninthesurgicaltreatmentofinfectedmassiveendoprosthesesimplantedformusculoskeletaltumours AT simonwarren riskfactorsforrecurrentinfectioninthesurgicaltreatmentofinfectedmassiveendoprosthesesimplantedformusculoskeletaltumours AT willaston riskfactorsforrecurrentinfectioninthesurgicaltreatmentofinfectedmassiveendoprosthesesimplantedformusculoskeletaltumours AT robpollock riskfactorsforrecurrentinfectioninthesurgicaltreatmentofinfectedmassiveendoprosthesesimplantedformusculoskeletaltumours AT craiggerrand riskfactorsforrecurrentinfectioninthesurgicaltreatmentofinfectedmassiveendoprosthesesimplantedformusculoskeletaltumours |